News and Events - Cardionovum®

Latest press release

Jan 17, 2021

APERTO DCB “superior” for AV fistulae lesions in new RCT.

Professor Dr Qizhuang Jin (Peking University First Hospital Nephrology Department, China) spoke to LINC Today about the recently published results of the first randomised controlled trial (RCT) comparing the APERTO® drug-coated balloon (DCB) with high pressure angioplasty balloon in the treatment of arteriovenous fistulae (AVF) lesions.

Learn more >> APERTO DCB “superior” for AV fistulae lesions in new RCT.

Jan 10, 2021

APERTO DCB “promising” for central venous stenosis in haemodialysis patients.

In a Q&A with LINC Today, Michael Lichtenberg, angiologist at Klinikum Hochsauerland GmbH, Arnsberg, Germany, discussed the APERTO® OTW (over-the-wire) drug coated balloon (DCB) currently being trialled in haemodialysis patients with central venous stenosis (CVS) in a bid to improve patency of arteriovenous fistulas (AVFs).

Learn more >> APERTO DCB “promising” for central venous stenosis in haemodialysis patients.

May 09, 2020

Cardionovum - first transcontinental China-Europe Webinar on the treatment of complications in arteriovenous access in dialysis patients during COVID-19 pandemic.

Guest from Europe: Prof. Michael Lichtenberg (Germany) & Prof. Matteo Tozzi (Italy).

Video of European guests' speech.

Learn more >> Cardionovum - first transcontinental China-Europe Webinar on the treatment of complications in arteriovenous access in dialysis patients during COVID-19 pandemic.

Apr 20, 2020

APERTO OTW® Drug Coated Balloon receives first Chinese NMPA Medical Device Registration Certificate for High Pressure DCB for Vascular Access

APERTO®, our innovative paclitaxel coated balloon for arterio-venous access, has received market approval for China. It is the the first high pressure drug coated balloon available in China to treat obstructive lesions of native Arterio Venous Dialysis Fistulae.

The approval was given based on the statistic results from the solidly designed clinical study in Chinese population:
APERTO AVF RCT CHINA.

Learn more >> APERTO OTW® Drug Coated Balloon receives first Chinese NMPA Medical Device Registration Certificate for High Pressure DCB for Vascular Access

Apr 02, 2020

Online Seminar: "CARDIOLOGY CARING in COVID-19 PANDEMICS" China-EU

European Key Opinion Leaders as guests:

Prof. Dr. Horst Sievert , Frankfurt, Germany
Prof. Dr. Giuseppe Tarantini, Padua, Italy
Prof. Dr. Jacques Blacher, Paris, France

Video of European guests' speech.

Learn more >> Online Seminar: "CARDIOLOGY CARING in COVID-19 PANDEMICS" China-EU

Oct 28, 2019

RESTORE® Drug-Coated Balloon receives first Chinese FDA medical device registration certificate for two indications

RESTORE^®, CARDIONOVUM’s innovative paclitaxel-coated balloon for coronary applications has received market approval for China, making it the first drug-coated balloon (DCB) available in China to treat two indications: in-stent restenosis (ISR) and small vessel disease (SVD). The approval was given based on the impressive results from two solidly designed clinical studies in Chinese populations: RESTORE ISR CHINA and RESTORE SVD CHINA.

Learn more >> RESTORE® Drug-Coated Balloon receives first Chinese FDA medical device registration certificate for two indications